Login
Super Investors Paradigm Biocapital Advisors LP
PB

Paradigm Biocapital Advisors LP

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$5.03B
Positions
30
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (20 quarters reported)

$5.34B $350M
Q4 21 Q4 22 Q4 23 Q4 24 Q4 25 Q3 26

$350M in Q4 2021 → $5.03B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Revolution Medicines Inc 25.4% Trimmed 2.2% 6,219,323 $1.28B
Genmab A/s 10.0% Added 7.6% 14,136,472 $504M
Edgewise Therapeutics Inc 8.7% Added 5.5% 10,778,665 $438M
Spyre Therapeutics Inc 7.9% Added 16% 4,457,450 $397M
Insmed Inc 6.1% Added 103% 2,695,977 $308M
Mbx Biosciences Inc 4.4% Added 50% 3,772,885 $221M
Oruka Therapeutics Inc 4.1% Added 16% 2,493,507 $208M
Belite Bio Inc 3.9% Trimmed 7.4% 1,142,123 $194M
Tarsus Pharmaceuticals Inc 3.6% Trimmed 17% 2,301,375 $181M
Tango Therapeutics Inc 3.5% Added 9.5% 6,961,546 $174M
VT Viridian Therapeutics Inc 3.4% Added 23% 8,257,672 $170M
Bridgebio Pharma Inc 3.1% New 2,347,850 $154M
Vaxcyte Inc 2.4% Added 0.7% 2,142,852 $122M
Erasca Inc 2.3% Trimmed 16% 7,998,257 $117M
Jade Biosciences Inc 1.7% Added 112% 6,053,268 $85M
Tyra Biosciences Inc 1.5% Added 92% 3,510,360 $76.8M
Olema Pharmaceuticals Inc 1.5% Added 0.6% 8,720,576 $75.3M
Obsidian Therapeutics Inc 1.1% New 4,155,214 $57.1M
Structure Therapeutics Inc 0.8% New 1,299,199 $40.6M
AL Achieve Life Science Inc 0.8% Unchanged 4,951,856 $40.1M
Veradermics Inc 0.7% New 310,060 $37.6M
Assembly Biosciences Inc 0.7% Unchanged 1,553,748 $36.5M
Oric Pharmaceuticals Inc 0.4% New 1,505,769 $20.3M
Korsana Biosciences Inc 0.4% New 613,914 $19.6M
Editas Medicine Inc 0.4% Added 36% 7,575,140 $19.5M
HT Hemab Therapeutics Hldgs Inc 0.4% New 629,347 $19.4M
Vor Biopharma Inc 0.3% Trimmed 49% 889,575 $17M
K Kardigan Inc 0.3% Unchanged 900,000 $13.3M
TA Tcgx Acquisition Corp 0.1% New 300,000 $3.75M
IS Inventiva Sa 0.1% Trimmed 80% 808,176 $2.98M

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Nuvalent Inc Exited −5,924,433 −$732M —
Apogee Therapeutics Inc Exited −1,576,385 −$209M —
Insmed Inc Added +1,370,000 +$156M 6.1%
Bridgebio Pharma Inc New +2,347,850 +$154M 3.1%
Alnylam Pharmaceuticals Inc Exited −480,000 −$144M —
Mbx Biosciences Inc Added +1,264,870 +$74.1M 4.4%
Obsidian Therapeutics Inc New +4,155,214 +$57.1M 1.1%
Spyre Therapeutics Inc Added +616,672 +$54.9M 7.9%
Jade Biosciences Inc Added +3,195,863 +$44.9M 1.7%
Eyepoint Inc Exited −2,890,397 −$41.3M —

Showing the 10 largest of 33 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Arcellx Inc Exited −5,774,016 −$663M —
Spyre Therapeutics Inc Added +1,883,512 +$167M 6.4%
Vaxcyte Inc Trimmed −2,665,168 −$155M 2.3%
Alnylam Pharmaceuticals Inc New +480,000 +$144M 2.7%
Centessa Pharmaceuticals PLC Exited −3,574,048 −$142M —
Genmab A/s Added +5,165,295 +$142M 6.8%
Mbx Biosciences Inc New +2,508,015 +$138M 2.6%
Terns Pharmaceuticals Inc Exited −2,216,499 −$117M —
Edgewise Therapeutics Inc Added +2,850,417 +$116M 7.8%
Cytokinetics Inc Exited −1,480,857 −$97.6M —

Showing the 10 largest of 40 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Insmed Inc New +1,254,488 +$205M 4.2%
SS SPDR Series Trust Exited −1,500,000 −$183M —
Belite Bio Inc New +1,114,784 +$178M 3.6%
Cidara Therapeutics Inc Exited −759,565 −$168M —
Centessa Pharmaceuticals PLC New +3,574,048 +$142M 2.9%
CP Crinetics Pharmaceuticals In Exited −2,210,774 −$103M —
Cytokinetics Inc New +1,480,857 +$97.6M 2.0%
SR Scholar Rock Hldg Corp Trimmed −1,836,077 −$90.3M 1.2%
Tango Therapeutics Inc New +4,009,679 +$83.9M 1.7%
Maze Therapeutics Inc New +2,744,399 +$81.9M 1.7%

Showing the 10 largest of 35 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
Merus N V Exited −4,373,770 −$412M —
Agios Pharmaceuticals Inc Exited −2,673,555 −$107M —
Genmab A/s Added +3,222,983 +$99.3M 5.5%
Janux Therapeutics Inc Exited −2,920,258 −$71.4M —
Arcellx Inc Added +1,075,000 +$70.1M 9.5%
SS SPDR Series Trust Added +500,000 +$61M 4.7%
Oruka Therapeutics Inc New +1,710,316 +$51.8M 1.3%
Alkermes PLC Exited −1,719,334 −$51.6M —
Lenz Therapeutics Inc Exited −1,073,461 −$50M —
Lexeo Therapeutics Inc New +4,763,198 +$47.3M 1.2%

Showing the 10 largest of 41 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
AS Abivax Sa New +1,564,196 +$133M 3.8%
Genmab A/s New +3,816,851 +$117M 3.3%
Cogent Biosciences Inc Trimmed −7,196,051 −$103M 1.3%
SS SPDR Series Trust New +1,000,000 +$100M 2.8%
Cidara Therapeutics Inc New +961,164 +$92M 2.6%
Beone Medicines Ltd Exited −347,787 −$84.2M —
Urogen Pharma Ltd New +4,216,084 +$84.1M 2.4%
Disc Medicine Inc Trimmed −963,255 −$63.7M 0.5%
Agios Pharmaceuticals Inc Added +1,531,044 +$61.5M 3.1%
Moonlake Immunotherapeutics Exited −878,323 −$41.5M —

Showing the 10 largest of 38 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Beone Medicines Ltd Trimmed −318,237 −$77M 3.6%
SR Scholar Rock Hldg Corp New +1,600,554 +$56.7M 2.4%
Vaxcyte Inc Added +1,676,356 +$54.5M 4.7%
Merus N V Added +912,255 +$48M 9.6%
Bridgebio Pharma Inc New +965,764 +$41.7M 1.8%
Alkermes PLC New +1,375,569 +$39.4M 1.7%
Agios Pharmaceuticals Inc New +1,142,511 +$38M 1.6%
Argenx Se Exited −59,679 −$35.3M —
Cytokinetics Inc Exited −858,664 −$34.5M —
Insmed Inc Exited −451,359 −$34.4M —

Showing the 10 largest of 31 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
Argenx Se Trimmed −421,626 −$250M 1.6%
Merus N V Added +1,679,777 +$70.7M 6.5%
VT Vera Therapeutics Inc Exited −1,437,339 −$60.8M —
Moonlake Immunotherapeutics Trimmed −1,144,788 −$44.7M 1.1%
Pliant Therapeutics Inc Exited −3,197,050 −$42.1M —
Cytokinetics Inc New +858,664 +$34.5M 1.6%
Insmed Inc New +451,359 +$34.4M 1.6%
Metsera Inc New +1,191,462 +$32.4M 1.5%
Cogent Biosciences Inc Added +4,046,243 +$24.2M 2.5%
Arcutis Biotherapeutics Inc New +1,465,334 +$22.9M 1.0%

Showing the 10 largest of 33 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
Kura Oncology Inc Exited −4,331,321 −$84.6M —
Beigene Ltd Added +415,688 +$76.8M 4.0%
Arcellx Inc Exited −800,000 −$66.8M —
Vaxcyte Inc Added +795,055 +$65.1M 4.1%
Janux Therapeutics Inc Added +1,115,412 +$59.7M 6.5%
Arvinas Inc Exited −2,339,961 −$57.6M —
Revolution Medicines Inc Added +1,239,022 +$54.2M 10.0%
Moonlake Immunotherapeutics Added +840,731 +$45.5M 3.3%
Edgewise Therapeutics Inc Added +1,704,757 +$45.5M 4.2%
Immunovant Inc Exited −1,362,827 −$38.9M —

Showing the 10 largest of 36 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support